周末要闻及周策略丨多重政策护航，跨年行情要来了？

Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have issued new drug directories for basic medical insurance and commercial health insurance, adding 114 new drugs, including 50 innovative drugs [1] - The China Securities Regulatory Commission has set clear requirements for market value management, cash dividends, and share buybacks to enhance the investment value of listed companies and increase investor returns [1] - The Financial Regulatory Administration has adjusted the risk factors for insurance companies' stock investments, aiming to cultivate and expand patient capital [1] Group 2 - The A-share market has shown a recovery, with major indices closing in the green, and the Shanghai Composite Index surpassing 3900 points [2] - Recent financial regulatory policies are expected to provide significant short-term support to the market, including differentiated supervision for quality institutions and the relaxation of capital and leverage restrictions [2] - Historical data indicates that the period from mid-December to mid-January is typically a key observation window for year-end market trends, coinciding with the release of annual policies and seasonal liquidity easing [2] Group 3 - In terms of sector allocation, the brokerage sector may benefit from regulatory policy optimization, while high-dividend stocks in banking, electricity, and home appliances remain attractive [3] - Growth sectors such as AI applications, robotics, and innovative pharmaceuticals are expected to have recovery potential if the spring market rally starts early [3] Group 4 - Upcoming IPOs include companies like Nabai Chuan, Yuxun Co., and Yuanchuang Co., with a focus on sectors such as new energy vehicle thermal management and optical communication [9]